These polymorphisms may not alter the CTLA-4 amino-acid sequence but can affect the affinity for CTLA-4 mAbs, thereby increasing the risk of immunotherapy-induced autoimmune disorders [72]. This evidence concerns the gene CTLA4 and Autoimmunity.